Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Oct 09, 2025 8:30 am EDT

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 03, 2025 12:28 pm EDT

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 03, 2025 12:19 pm EDT

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025 8:30 am EDT

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025 8:30 am EDT

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025 8:30 am EDT

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025 8:30 am EDT

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 08, 2025 8:30 am EDT

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 04, 2025 8:30 am EDT

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025 8:30 am EDT

IceCure Reports Financial & Operational Results for the First Half of 2025

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023